stockrowCorcept Therapeutics Incorporated
CORT Healthcare Biotechnology
Corcept Therapeutics Incorporated’s revenue for fiscal 2025 (year ended December 2025) was $761.4 million, up 12.8% from fiscal 2024.
- Revenue
- +64.0%
- EPS
- +525.8%
- Free cash flow
- +161.0%
Quarter to September 2026, against a year earlier
Follow CORT
Alert me
Corcept Therapeutics Incorporated (CORT) Return on assets
Corcept Therapeutics Incorporated's return on assets over the twelve months to 30 September 2026 was 17.2%, up 5.4 percentage points from fiscal 2025 (11.7%). Over the past ten years it has ranged from −14.8% (fiscal 2015) to 89.3% (fiscal 2017); the current reading is higher than 18% of that period. That is above the Biotechnology industry median of −45.6% and above the Healthcare sector median of −29.3%.
Return on assets, annual
Embed this chart
Annual newest first
| Period | Return on assets | Change (points) |
|---|---|---|
| FY2025 | 11.7% | (7.40) |
| FY2024 | 19.1% | 1.60 |
| FY2023 | 17.5% | (2.60) |
| FY2022 | 20.1% | (2.49) |
| FY2021 | 22.6% | 1.05 |
| FY2020 | 21.6% | (4.47) |
| FY2019 | 26.0% | (2.32) |
| FY2018 | 28.3% | (60.93) |
| FY2017 | 89.3% | 75.78 |
| FY2016 | 13.5% | 28.30 |
Against its own ten years
Return on assets against peers
| Company | Return on assets |
|---|---|
| CORT Corcept Therapeutics Incorporated | 17.2% |
| KRYS Krystal Biotech, Inc. compare | 15.9% |
| PTGX Protagonist Therapeutics, Inc. compare | 10.3% |
| MDGL Madrigal Pharmaceuticals, Inc. compare | −11.1% |
| ARWR Arrowhead Pharmaceuticals, Inc. compare | −18.3% |
| SYRE Spyre Therapeutics, Inc. compare | −30.9% |
| PRAX Praxis Precision Medicines, Inc. compare | −36.8% |
| CYTK Cytokinetics, Incorporated compare | −47.7% |
| ABVX Abivax SA Sponsored ADR compare | −137.7% |
| Biotechnology industry median | −45.6% |
| Healthcare sector median | −29.3% |
| Market median | 0.00% |
What Return on assets is
ROA tells an investor how much profit a company earns for shareholders from the assets it uses to run its business.
Annual: Net Income Allotted to Shareholders ÷ Average Assets; TTM: Net Income Allotted to Shareholders ÷ Average Assets (latest quarter)
More on CORT
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement